Trial Profile
A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Aug 2019
Price :
$35
*
At a glance
- Drugs Interferon alpha (Primary) ; MVA 5T4 (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Oxford BioMedica; Sanofi
- 02 Aug 2019 Status changed from active, no longer recruiting to completed.
- 15 Jun 2008 New trial record.
- 02 Jun 2008 Trial results reported at American Society of Clinical Oncology annual meeting in 2008.